Clinical trial
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
NCT00088231 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00088231 |
|---|---|
| Title | PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP |
| Official title | Ph I/II Study of PTK 787 (Vatalanib) and Gleevec (Imatinib) in Patients With Refractory Acute Myelogenous Leukemia (AML), Agnogenic Myeloid Metaplasia (AMM), and Chronic Myelogenous Leukemia- Blastic Phase (CML-BP) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia, Agnogenic Myeloid Metaplasia, Chronic Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Imatinib Mesylate (Gleevec), PTK 787 (vatalanib) |
| Enrollment | 9 |
| Start date | Jul 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Jul 23, 2004 |
| Last update posted | Jan 20, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: